Syros to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call on November 5, 2020, at 4:30 p.m. ET, to report its Q3 2020 financial results and provide a corporate update. Investors can join the call by dialing 866-595-4538 (domestic) or 636-812-6496 (international), with the conference ID 1088286. A webcast will also be available on Syros' website, offering an archived replay for 30 days post-call. The company is focused on developing innovative treatments for diseases through gene expression control, with key programs including SY-1425 and SY-5609 in clinical trials.
- Syros is advancing its pipeline with SY-1425 in Phase 2 for acute myeloid leukemia and SY-5609 in Phase 1 for solid tumors.
- None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 4:30 p.m. ET on Thursday, November 5, 2020 to report its third quarter 2020 financial results and provide a corporate update.
To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 1088286. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in a Phase 1 trial in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
